Cited by 186Retinal Development and DisordersRetinal Diseases and TreatmentsLysosomal Storage Disorders Research

ABCA4 disease progression and a proposed strategy for gene therapy

Open access
Cideciyan, Artur V., Swider, Malgorzata, Aleman, Tomas S., Tsybovsky, Yaroslav, Schwartz, Sharon B., Windsor, Elizabeth A.M., Roman, Alejandro J., Sumaroka, Alexander +4 more·2009·Human Molecular Genetics

Abstract

Autosomal recessive retinal diseases caused by mutations in the ABCA4 gene are being considered for gene replacement therapy. All individuals with ABCA4-disease show macular degeneration, but only some are thought to progress to retina-wide blindness. It is currently not predictable if or when specific ABCA4 genotypes will show extramacular disease, and how fast it will progress thereafter. Early clinical trials of focal subretinal gene therapy will aim to arrest disease progression in the extramacular retina. In 66 individuals with known disease-causing ABCA4 alleles, we defined retina-wide disease expression by measuring rod- and cone-photoreceptor-mediated vision. Serial measurements over a mean period of 8.7 years were consistent with a model wherein a normal plateau phase of variable length was followed by initiation of retina-wide disease that progressed exponentially. Once initiated, the mean rate of disease progression was 1.1 log/decade for rods and 0.45 log/decade for cones. Spatio-temporal progression of disease could be described as the sum of two components, one with a central-to-peripheral gradient and the other with a uniform retina-wide pattern. Estimates of the age of disease initiation were used as a severity metric and contributions made by each ABCA4 allele were predicted. One-third of the non-truncating alleles were found to cause more severe disease than premature truncations supporting the existence of a pathogenic component beyond simple loss of function. Genotype-based inclusion/exclusion criteria and prediction of the age of retina-wide disease initiation will be invaluable for selecting appropriate candidates for clinical trials in ABCA4 disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/hmg/ddn421

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Lack of a functional ABCA4 transporter causes Stargardt disease, a juvenile form of macular degeneration, whereas some other changes are associated with AMD.

    “Here, lack of a functional transporter causes Stargardt disease,545,558,559 a juvenial form of macular degeneration, whereas some other changes were demonstrated to be associated with AMD.560,561”

    From Chemistry of the Retinoid (Visual) Cycle (2014) · cites this paper as [558]

    The Discussion links ABCA4 mutations to Stargardt disease (STGD), but describes a spectrum of disease rather than saying that complete loss of transporter function specifically causes STGD. It associates likely complete loss of function with some of the more severe retinal disease and notes that STGD can progress beyond the macula. The AMD clause has separate citations in the citing sentence, so it is not attributed to this source. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

5 of the 87 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Cideciyan, A. V., Swider, M., Aleman, T. S., Tsybovsky, Y., Schwartz, S. B., Windsor, E. A. M., Roman, A. J., Sumaroka, A., Steinberg, J. D., Jacobson, S. G., Stone, E. M., & Palczewski, K.
Affiliations
  • University of Pennsylvania (US)
  • Case Western Reserve University (US)
  • Howard Hughes Medical Institute (US)
Corresponding author
Cideciyan, Artur V.
Venue
Human Molecular Genetics
Published
2008-12-12
Volume
18
Issue
5
Pages
931-941
ISSN
  • 0964-6906 (ISSN-L)
  • 1460-2083
OpenAlex
W2164929411
Cited by
186
References
87
Citations by year
2026: 5 · 2025: 11 · 2024: 6 · 2023: 11 · 2022: 8 · 2021: 13 · 2020: 9 · 2019: 8 · 2018: 18 · 2017: 14 · 2016: 9 · 2015: 11 · 2014: 13 · 2013: 13 · 2012: 9
FWCI
3.84
Type
journal article
Language
en
Open access
Locations
  • Human Molecular Genetics (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • Research to Prevent Blindness
  • Macula Vision Research Foundation
  • Hope For Vision
  • National Institutes of Health (EY09339)
  • National Eye Institute (EY-13203, EY 09339, R01EY013203, R01EY009339)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinal Development and Disorders
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Physiology › Lysosomal Storage Disorders Research
Keywords
ABCA4, autosomal recessive retinal degeneration, macular degeneration, disease progression, gene replacement therapy, subretinal gene therapy, photoreceptors, rod photoreceptors, cone photoreceptors, genotype severity
MeSH terms
Adolescent, Adult, Aged, Child, Female, Genotype, Humans, Male, Middle Aged, Mutation, Pedigree, Retinal Diseases, Genetic Therapy, Cohort Studies, Age of Onset, Disease Progression, ATP-Binding Cassette Transporters, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review